CALC Should I Buy

Oppenheimer lowered the firm's price target on CalciMedica to $10 from $20 and keeps an Outperform rating on the shares. The firm notes CalciMedica reported updates to its programs in acute kidney injury and acute pancreatitis along with quarterly financials. The most important development is the absence of any drug-related toxicity following thorough internal/external review of the unblinded Phase 2 KOURAGE dataset - as CalciMedica had indicated after voluntarily discontinuing the trial in late January.